Form 4: Fate Therapeutics Director Receives Option Grant

Director Michael Lee was granted 87,900 stock options in Fate Therapeutics, which are held for the benefit of Redmile Group.

Summary

• Michael Lee, a director at Fate Therapeutics, received a grant of 87,900 stock options on June 12, 2026.
• The options have an exercise price of $2.06 per share.
• The options vest in full on the earlier of June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders.
• The economic and voting rights of these options are assigned to Redmile Group, LLC, where Mr. Lee serves as a managing director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The options vest in one year, contingent on continued board service.

Management Comments

• Mr. Lee disclaims beneficial ownership of the stock option award, noting it is held as a nominee for Redmile Group.
• Redmile and Jeremy Green are considered directors by deputization for Section 16 purposes.

Industry Context

StockSavvy.ai notes that equity grants to board members representing institutional investors are standard practice in the biotechnology sector to ensure alignment between venture capital backers and company governance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for mid-cap biotechnology firms.
• The use of 'director by deputization' is a common legal structure for venture capital firms holding board seats in portfolio companies.

Corporate Governance

Related Party Transactions

• Michael Lee is a managing director of Redmile Group, LLC, which is the beneficiary of the granted options.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 12, 2027, or the 2027 Annual Meeting.

Key Dates

Keywords

Fate Therapeutics, FATE, SEC Form 4, Stock Options, Redmile Group, Director Compensation, Insider Ownership